Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
Zhao Wang, Srinivasulu Cherukupalli, Minghui Xie, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 3729-3757
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use
Davide Benedetto Tiz, Luana Bagnoli, Ornelio Rosati, et al.
Molecules (2022) Vol. 27, Iss. 5, pp. 1643-1643
Open Access | Times Cited: 92
Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates
Murugaiah A. M. Subbaiah, Jarkko Rautio, Nicholas A. Meanwell
Chemical Society Reviews (2024) Vol. 53, Iss. 4, pp. 2099-2210
Closed Access | Times Cited: 24
The importance of binding kinetics and drug–target residence time in pharmacology
Kevin E. Knockenhauer, Robert A. Copeland
British Journal of Pharmacology (2023) Vol. 181, Iss. 21, pp. 4103-4116
Closed Access | Times Cited: 24
A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication
Belgin Sever, Masami Otsuka, Mikako Fujita, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3659-3659
Open Access | Times Cited: 11
DrugFlow: An AI-Driven One-Stop Platform for Innovative Drug Discovery
Chao Shen, Jianfei Song, Chang‐Yu Hsieh, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 14, pp. 5381-5391
Closed Access | Times Cited: 8
Quinolines and isoquinolines as HIV-1 inhibitors: Chemical structures, action targets, and biological activities
Sha Hu, Jiong Chen, Jin-Xu Cao, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106549-106549
Closed Access | Times Cited: 18
Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications
Zhen-Xi Niu, Jing Hu, Jinfeng Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116446-116446
Closed Access | Times Cited: 6
A Review on FDA Approved Anti-HIV-1 Drugs, Anti-Gag Compounds and Potential Strategies for HIV-1 Eradication
Belgin Sever, Masami Otsuka, Mikako Fujita, et al.
(2024)
Open Access | Times Cited: 5
Structure‐based design of diarylpyrimidines and triarylpyrimidines as potent HIV‐1 NNRTIs with improved metabolic stability and drug resistance profiles
Minghui Xie, Zhao Wang, Fabao Zhao, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Closed Access | Times Cited: 5
Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance
Kun Zhang, Yujie Zhang, Min Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 5
Bird's eye view of natural products for the development of new anti‐HIV agents: Understanding from a therapeutic viewpoint
Md. Al Amin, Mohamed H. Nafady, Mehrukh Zehravi, et al.
Animal Models and Experimental Medicine (2025)
Open Access
Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023
Sheng Han, Yiming Lu
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115586-115586
Closed Access | Times Cited: 15
Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties
Ladislav Prener, Ondřej Baszczyňski, Martin Kaiser, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1761-1777
Open Access | Times Cited: 12
Discovery of Noncovalent Diaminopyrimidine-based Inhibitors for Glioblastoma via a Dual FAK/DNA Targeting Strategy
Yi Wei, Xiaoling He, Zhiwu Long, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117288-117288
Closed Access
In situ click chemistry-based discovery of 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs by exploiting the tolerant region I in binding pocket
Yanying Sun, Da Feng, Zhenzhen Zhou, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 96, pp. 117484-117484
Closed Access | Times Cited: 10
Tri‐substituted 1,3,5‐triazine‐based analogs as effective HIV‐1 non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A systematic review
Zebabanu Khalifa, Amit B. Patel
Drug Development Research (2024) Vol. 85, Iss. 1
Closed Access | Times Cited: 3
Discovery of Novel Aryl Triazolone Dihydropyridines (ATDPs) Targeting Highly Conserved Residue W229 as Promising HIV-1 NNRTIs
Yanying Sun, Zhenzhen Zhou, Na Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6570-6584
Closed Access | Times Cited: 3
Fragment Addition-Based Design of Heteroaromatic-Biphenyl-DAPYs as Potent and Orally Available Non-nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Enhanced Safety
Wenjuan Huang, Christophe Pannecouque, Erik De Clercq, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Escaping from Flatland: Multiparameter Optimization Leads to the Discovery of Novel Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Human Immunodeficiency Virus-1 Non-nucleoside Reverse Transcriptase Inhibitors with Superior Antiviral Activities against Non-nucleoside Reverse Transcriptase Inhibitor-Resistant Variants and Favorable Drug-like Profiles
Zhao Wang, Prem P. Sharma, Brijesh Rathi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8643-8665
Closed Access | Times Cited: 9
Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety
Limin Zhao, Christophe Pannecouque, Erik De Clercq, et al.
Chinese Chemical Letters (2023) Vol. 34, Iss. 12, pp. 108261-108261
Closed Access | Times Cited: 8
Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility
Limin Zhao, Christophe Pannecouque, Erik De Clercq, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 12, pp. 4906-4917
Open Access | Times Cited: 7
Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization
Lanlan Jing, Gaochan Wu, Fabao Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116772-116772
Closed Access | Times Cited: 2
Expanding the Solvent/Protein Region Occupation of the Non-Nucleoside Reverse Transcriptase Inhibitor Binding Pocket for Improved Broad-Spectrum Anti-HIV-1 Efficacy: from Rigid Phenyl-Diarylpyrimidines to Flexible Hydrophilic Piperidine-Diarylpyrimidines
Wenjuan Huang, Christophe Pannecouque, Erik De Clercq, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 19889-19904
Closed Access | Times Cited: 2
Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors
Yaqing Zuo, Rongrong Li, Yan Zhang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 2742-2754
Open Access | Times Cited: 10
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin’s Interactions with Its Nuclear Partners
Hao Zhang, Chenglong Liu, Di Zhu, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 1-31
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top